Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07514260 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
A Phase 1 study, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07514260 is a Phase 1 study that is actively recruiting participants, run by AbbVie. The registered enrollment target is 24 participants.
The verdict
NCT07514260, a Phase 1 study, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
Interventions
- DRUG ABBV-295
- DRUG Placebo for ABBV-295
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07514260
The ClinicalTrials.gov registry entry for NCT07514260 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-295 is the first listed.
NCT07514260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07514260 about?
NCT07514260 is a clinical study titled "A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.". The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
What is the current status of trial NCT07514260?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-03-31. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07514260?
The interventions under investigation include: ABBV-295 (DRUG), Placebo for ABBV-295 (DRUG).
Who is sponsoring clinical trial NCT07514260?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.